Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses
Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 3
Abstract
The online version of this article (doi:10.1208/s12248-012-9373-2) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Ron J. Keizer, Anthe S. Zandvliet, Jos H. Beijnen, Jan H. M. Schellens, Alwin D. R. Huitema
Keywords
Related Articles
- EP ID EP681242
- DOI 10.1208/s12248-012-9373-2
- Views 101
- Downloads 0
Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease
Parkinson’s disease is an age-related degenerative disorder of the central nervous system that often impairs the sufferer’s motor skills and speech, as well as other functions. Symptoms can include tremor...
Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations
Immunogenicity is a significant concern for biologic drugs as it can affect both safety and efficacy. To date, the descriptions of product immunogenicity have varied not only due to different degrees of understanding of...
Case Studies for Practical Food Effect Assessments across BCS/BDDCS Class Compounds using In Silico, In Vitro, and Preclinical In Vivo Data
The online version of this article (doi:10.1208/s12248-012-9419-5) contains supplementary material, which is available to authorized users.
Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?
CT-P13, the world’s first biosimilar monoclonal antibody to infliximab, was approved for marketing in South Korea for all the six indications of infliximab, which Europe may follow, although the product was teste...
Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective
The online version of this article (doi:10.1208/s12248-013-9470-x) contains supplementary material, which is available to authorized users.